Table 2.
Fixed-Effects Regression Models Estimating the Effect of Escitalopram on Pain Severity and Pain Interference, Without and With Adjustment for Depression
| PAIN SEVERITY | PAIN INTERFERENCE | |||
|---|---|---|---|---|
| Model 1 | Model 2 | Model 1 | Model 2 | |
|
β
(SE) |
β
(SE) |
β
(SE) |
β
(SE) |
|
| Time a | −16.82** (3.74) |
−8.37 (4.50) |
−1.48** (0.40) |
−0.16 (0.51) |
| Treatment by Time b | −14.34** (5.39) |
−14.37** (5.34) |
−1.20* (0.54) |
−1.20* (0.52) |
| BDI (Time-Varying) | NA | 0.55* (0.22) |
NA | 0.09** (0.02) |
| Intercept | 48.89 | 33.47 | 4.01 | 1.60 |
*
p < .05
**
p < .01
a
Coefficient gives the expected change in pain between baseline and follow-up visits for participants randomized to placebo.
b
Relative to controls this coefficient gives the expected mean change between baseline and follow-up visits for participants randomized to escitalopram.